EUVIMEDObjevte EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Real‐World Data of Second‐Line Amrubicin Monotherapy in Patients With Extensive‐Stage Small Cell Lung Cancer Who Received First‐Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study

Kei Sonehara iD, Toshiharu Tsutsui iD, Shuhei Nozawa, Toshihiko Agatsuma, Manabu Yamamoto, Akemi Matsuo, Masanori Nakanishi, Tomoshige Chiaki, Akane Kato, Takashige Miyahara, Tsutomu Hachiya, Shintaro Kanda and 5 more

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71982 ↗

At a glance

Multizentrische Studie in Cancer Medicine, published online on 2026-05-22. Written by Kei Sonehara and 16 co-authors. Institution: First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. Major MEDLINE topics: Anthracyclines, Antineoplastic Agents, Lung Neoplasms, Small Cell Lung Carcinoma. Cited 1 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Chemoimmunotherapy is widely used as the first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), but treatment options for second‐line have not changed. Amrubicin monotherapy is used as the standard treatment for relapsed SCLC, but since chemoimmunotherapy became an additional indication for ES‐SCLC, the efficacy and safety of second‐line amrubicin have not been sufficiently investigated.

Methods

We enrolled a total of 131 relapsed SCLC patients who received second‐line amrubicin at eleven institutions in Japan between August 2019 and June 2023. We retrospectively examined the efficacy and safety of second‐line amrubicin monotherapy.

Results

Twenty‐five (19.1%) and 106 patients (80.9%) had sensitive and refractory relapse, respectively. 51 (38.9%) and 80 (61.1%) patients received first‐line chemoimmunotherapy and first‐line chemotherapy, respectively. The median progression‐free survival (PFS) and overall survival (OS) were 3.6 months (95% confidence interval [CI], 3.1–4.1 months) and 7.9 months (95% CI, 6.7–9.1 months), respectively. The median PFS and OS were significantly longer in the sensitive group compared with the refractory group (PFS: 6.4 vs. 3.5 months, p = 0.008, OS: 9.4 vs. 6.4 months, p = 0.021, respectively). Treatment‐related adverse events were as follows: Grade 4 neutropenia in 51 patients (38.9%), grade 3 or higher febrile neutropenia in 18 patients (13.7%), and all grade interstitial lung disease in 13 patients (9.9%). Treatment‐related death was 1 patient (0.8%).

Conclusion

Second‐line amrubicin monotherapy for relapsed SCLC may be useful and well‐tolerated as a treatment option after first‐line chemoimmunotherapy or chemotherapy.

Subjects

MeSH terms (MEDLINE)

AnthracyclinesAntineoplastic AgentsLung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedImmunotherapyJapanNeoplasm Recurrence, LocalNeoplasm StagingRetrospective Studies

Substances

amrubicinAnthracyclinesAntineoplastic Agents

Authors and institutions

  • First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Respiratory Medicine, Yamanashi Prefectural Central Hospital, Kofu, Japan.
  • Department of Respiratory Medicine, Nagano Municipal Hospital, Nagano, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Shinshu Ueda Medical Center, Ueda, Japan.
  • Department of Respiratory Medicine, Nagano Red Cross Hospital, Nagano, Japan.
  • Department of Respiratory Medicine, Minaminagano Medical Center, Shinonoi General Hospital, Nagano, Japan.

ORCID profiles: Kei Sonehara, Toshiharu Tsutsui, Kazunari Tateishi

Cite

APA

Sonehara, K., Tsutsui, T., Nozawa, S., Agatsuma, T., Yamamoto, M., Matsuo, A., Nakanishi, M., Chiaki, T., Kato, A., Miyahara, T., Hachiya, T., Kanda, S., Hirabayashi, T., Yanagisawa, K., Araki, T., Tateishi, K., & Hanaoka, M. (2026). Real‐World Data of Second‐Line Amrubicin Monotherapy in Patients With Extensive‐Stage Small Cell Lung Cancer Who Received First‐Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71982

Vancouver

Sonehara K, Tsutsui T, Nozawa S, Agatsuma T, Yamamoto M, Matsuo A, et al. Real‐World Data of Second‐Line Amrubicin Monotherapy in Patients With Extensive‐Stage Small Cell Lung Cancer Who Received First‐Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71982

BibTeX
@article{Sonehara2026,
  author = {Sonehara, Kei and Tsutsui, Toshiharu and Nozawa, Shuhei and Agatsuma, Toshihiko and Yamamoto, Manabu and Matsuo, Akemi and Nakanishi, Masanori and Chiaki, Tomoshige and Kato, Akane and Miyahara, Takashige and Hachiya, Tsutomu and Kanda, Shintaro and Hirabayashi, Taro and Yanagisawa, Katsuya and Araki, Taisuke and Tateishi, Kazunari and Hanaoka, Masayuki},
  title = {Real‐World Data of Second‐Line Amrubicin Monotherapy in Patients With Extensive‐Stage Small Cell Lung Cancer Who Received First‐Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71982}
}
Start for free →